Tango Therapeutics Announces the Addition of Shakti Narayan, PhD, JD as Chief Business Officer
CAMBRIDGE, Mass., December 6, 2017 – Tango Therapeutics, a biotechnology company creating novel, targeted medicines for specific cancer subtypes, today announced that Shakti Narayan, PhD, JD, has joined the company as Tango’s Chief Business Officer.
Narayan brings extensive leadership experience in business development, operations and legal operations within the biotechnology and pharmaceuticals industries, most recently through his role as Vice President and Head of Transactions at Johnson & Johnson (J&J) Innovation in Boston. At J&J, he helped build the company’s Innovation Centers model, where he led oncology business development efforts and led a team that drove strategic transactions spanning multiple J&J businesses. His full biography is available here.
In addition, Tango announced today that Dimitris Papoutsakis, PhD, has joined the company as Vice President of Operations, Program and Portfolio Management. Dimitris joins Tango from Novartis Oncology, where he worked most recently in oncology business development and licensing roles. In addition, Tania Philipp has joined the company as Vice President of Human Resources from global human resources at Bavarian Nordic.
“We are thrilled to add these talented and committed individuals to our senior leadership team as we build a world-class drug discovery and development organization that is leading the way in creating new synthetic lethal approaches for cancer,” said Barbara Weber, MD, Tango’s Chief Executive Officer. “Shakti’s track record in establishing strong partnerships to advance promising early discoveries will support an important pillar of our strategy as we develop the broad potential of our platform through both our own internal efforts, and through activities we undertake with partners.”
About Tango Therapeutics
Tango Therapeutics, a 2017 “Fierce 15” company, is a biotechnology company developing novel therapies targeting context-dependent vulnerabilities in cancers. Tango’s robust product engine is designed to support the discovery and development of breakthrough medicines that provide deeper, more sustained benefit than today’s targeted therapies, and that extend the benefits of available immuno-oncology agents. The company’s programs are focused in the area of synthetic lethality, the interaction between two genes that causes cell death when both are inactivated. Tango was launched in 2017 with a $55 million Series A investment funded by Third Rock Ventures. For more information, please visit www.tangotx.com.
Dan Quinn, Ten Bridge Communications